III. Contraindications

IV. Mechanism

  1. See Interferon Alfa-2B
  2. Pegylated Interferon is recombinant Interferon alfa conjugated to Polyethylene Glycol (PEG)
    1. PEG component decreases Interferon clearance and extends its therapeutic effects
    2. Pegylated Interferon is typically preferred over the non-pegylated Interferon (e.g. Interferon Alfa-2B)

V. Dosing: Chronic Hepatitis B Infection

  1. Store in refrigerator
  2. Adult
    1. Dose 180 mg SQ in Abdomen or thigh once weekly for 48 weeks
  3. Renal: Decrease dose if eGFR <30 ml/min or Hemodialysis
    1. Dose 135 mcg SQ weekly

VI. Adverse Effects

VII. Safety

  1. Pregnancy Category C
  2. Avoid in Lactation

VIII. Monitoring

Images: Related links to external sites (from Bing)

Related Studies

Ontology: peginterferon alfa-2a (C0391001)

Definition (NCI) A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. (NCI04)
Definition (NCI_NCI-GLOSS) A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.
Definition (PDQ) A covalent conjugate of recombinant interferon alfa, subtype 2a, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2a protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=335280&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=335280&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C33987" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116)
MSH C100416
SnomedCT 421559001, 398841009
English PEG-IFN alfa-2A, PEG-IFN alpha-2A, PEG-interferon alfa-2A, PEGINTERFERON ALFA-2A @ @ UNIDENTIFIED, PEGINTERFERON ALFA-2A UNIDENTIFIED, Peginterferon alpha-2a (substance), Peginterferon alpha-2a, PEG-Interferon Alfa-2a, PEG-IFN alfa-2a, PEG-interferon alfa-2a, polyethylene glycol-interferon alfa-2a, PEG-IFN alpha-2a, PEG-interferon alpha-2a, peginterferon alpha-2a, pegylated interferon alpha-2a, polyethylene glycol-interferon alpha-2a, peginterferon alfa-2a [Chemical/Ingredient], peginterferon alpha-2a (medication), peg-interferon alfa-2a, pegylated interferon alfa-2a, Peginterferon alfa-2a (product), Peginterferon alfa-2a, PEG-IFNA2a, peginterferon alfa-2a, polyethylene glycol-interferon alfa-2A, PEGINTERFERON ALFA-2A, Peginterferon Alfa-2a
Spanish peginterferón alfa-2a (sustancia), peginterferón alfa-2a, cefalea posmielografía (producto), cefalea posmielografía